Precancerous Conditions and Risk Factors for Pancreatic and Bile Duct Cancer

Czech version

Authors: I. Novotný
Authors‘ workplace: Gastroenterologické oddělení, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2013; 26(Supplementum): 29-33

Overview

Pancreatic cancer has one of the worst prognoses of any type of cancer. Early detection and surgery is the best chance for cure. However, symptoms are typically vague and occur when the cancer is unresectable. Early detection through screening is likely to be the best hope to improve survival. The relatively low incidence of pancreatic cancer and the insensitive screening techniques currently available render this approach expensive and inefficient in the general population. Early detection and screening for pancreatic cancer in the current state should be limited to high‑risk patiens. But hereditary factors account about 10% of patients with pancreatic cancer (familial pancreatic cancer, hereditary pancreatitis, Peutz‑ Jegher’s syndrom etc.). Continued efforts are needed to discover effective test to identify patients with nonhereditary risk factors who will benefit from screening and also to develop less invasive and more cost‑effective screening modalities aimed at controlling pancreatic cancer. A combined approach of serum markers, genetic markers and specific imaging studies may prove to be the future of pancreatic screening.

Key words:
pancreatic cancer – gallbladder cancer – precancerous conditions – risk factors

The author declare he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
16. 9. 2013

Accepted:
27. 9. 2013

Sources

1. Nakao A, Harada A, Nonami T et al. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996; 12(4): 357– 361.

2. Ariyama J, Suyama M, Satoh K et al. Imaging of small pancreatic ductal adenocarcinoma. Pancreas 1998; 16(3): 396– 401.

3. Egawa S, Takeda K, Fukuyama S et al. Clinicopathological aspects of small pancreatic cancer. Pancreas 2004; 28(3): 235– 240.

4. Steinberg W. The clinical utility of the CA 19- 9 tumor‑associated antigen. Am J Gastroenterol 1990; 85(4): 350– 355.

5. Parra JL, Kaplan S, Barkin JS. Elevated CA 19- 9 caused by Hashimoto‘s thyroiditis: review of the benign causes of increased CA 19-9 level. Dig Dis Sci 2005; 50(4): 694– 695.

6. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19- 9. Med J Malaysia 2003; 58(5): 667– 672.

7. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7(1): 66– 86.

8. Kim JE, Lee KT, Lee JK et al. Clinical usefulness of carbohydrate antigen 19– 9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19(2): 182– 186.

9. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24(33): 5313– 5327.

10. DeWitt J, Devereaux B, Chriswell M et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med 2004; 141(10): 753– 763.

11. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7(1): 66– 86.

12. Goh BK, Tan YM, Chung YF. Utility of fusion CT‑ PET in the diagnosis of small pancreatic carcinoma. World J Gastroenterol 2005; 11(24): 3800– 3802.

13. Yan L, McFaul C, Howes N et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high‑risk groups. Gastroenterology 2005; 128(7): 2124– 2130.

14. Nakashima A, Murakami Y, Uemura K et al. Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas 2009; 38(5): 527– 533.

15. Lowenfels AB, Maisonneuve P, DiMagno EP et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89(6): 442– 446.

16. Klein AP, Brune KA, Petersen GM et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64(7): 2634– 2638.

17. McFaul CD, Greenhalf W, Earl J et al. Anticipation in familial pancreatic cancer. Gut 2006; 55(2): 252– 258.

18. Neglia JP, FitzSimmons SC, Maisonneuve P et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332(8): 494– 499.

19. Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz‑ Jeghers Syndrome. Gastroenterology 2000; 119(6): 1447– 1453.

20. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kincohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98(23): 1694– 1706.

21. Fuchs CS, Colditz GA, Stampfer MJ et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156(19): 2255– 2260.

22. Huxley R, Ansary‑ Moghaddam A, Berrington de González A et al. Type‑ II diabetes and pancreatic cancer: a meta‑analysis of 36 studies. Br J Cancer 2005; 92(11): 2076– 2083.

23. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young‑ onset diabetes: systematic review and meta‑analysis. Br J Cancer 2007; 96(3): 507– 509.

24. Chari ST, Leibson CL, Rabe KG et al. Probability of pancreatic cancer following diabetes: a population‑based study. Gastroenterology 2005; 129(2): 504– 511.

25. Lowenfels AB, Maisonneuve P, Cavallini G et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328(20): 1433– 1437.

26. Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high‑risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4(6): 766– 781.